Francesco Spagnolo

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Pier Francesco Ferrucci, Paolo A. Ascierto, Jacopo Pigozzo et al. · Annals of Oncology · 2016 · 395 citations · Full text

Medicine, Hematology, Oncology +17

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci et al. · Journal of Clinical Oncology · 2022 · 220 citations

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Georgina V. Long, Jason J. Luke, Muhammad A. Khattak et al. · The Lancet Oncology · 2022 · 147 citations

Medicine, Clinical Sciences, Oncology +15

The treatment of advanced melanoma: Current approaches and new challenges

Andrea Boutros, Elena Croce, Marco Ferrari et al. · Critical Reviews in Oncology/Hematology · 2024 · 143 citations · Full text

Medicine, Oncology, Pharmacotherapy +17